Sotera Health Co (SHC): Cost of Revenue
$518.08M
Year ended 2025-12-31
$547.66M
Trailing 12 months to 2026-06-30
+5.1%
3-year compound annual growth
+6.7%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $518.08M | +4.0% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $498.15M | +5.5% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $472.13M | +5.7% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $446.68M | +8.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $412.81M | +10.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $374.59M | -2.2% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $382.90M | n/a | 2022-03-01, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Sotera Health Co (SHC) | 2025-12-31 | $518.08M | +4.0% |
| Progyny, Inc. (PGNY) | 2025-12-31 | $984.18M | +7.7% |
| Viemed Healthcare, Inc. (VMD) | 2025-12-31 | $114.82M | +26.1% |
| Cryo Cell International Inc (CCEL) | 2025-11-30 | $7.38M | -7.2% |
| Charming Medical Ltd (MCTA) | 2026-03-31 | $35.2K | +127.0% |
| Mangoceuticals, Inc. (MGRX) | 2025-12-31 | $54.4K | -41.7% |
| BioRestorative Therapies, Inc. (BRTX) | 2025-12-31 | $23.8K | -15.1% |
Compare SHC, PGNY, VMD, CCEL side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗